URGN

UroGen Pharma (URGN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.

Earnings

UroGen CEO 'Very Surprised' As Rival Trials Drain Starts For Jelmyto, Now Guided To About $90 Million

Four or five companies are enrolling the same small patient pool, CEO Liz Barrett said, and the lost starts add up to several million dollars a year.

Earnings

UroGen's Quarterly Loss Shrinks To $1.5 Million As ZUSDURI Sales Hit $68.0 Million, But JELMYTO Outlook Drops

The cancer drugmaker cut its 2026 JELMYTO sales forecast to about $90 million even as total third-quarter revenue reached $89.0 million.